These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 12092741)

  • 1. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.
    Fossler MJ; Ebling WF; Ma S; Kornhauser D; Mondick J; Barrett JS; Garner D; Quon CY; Pieniaszek HJ
    J Clin Pharmacol; 2002 Dec; 42(12):1326-34. PubMed ID: 12463727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
    Mousa SA; Kapil R; Mu DX
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
    Mousa SA; Bozarth JM; Seiffert D; Feuerstein GZ
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):165-71. PubMed ID: 15795533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
    Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
    Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
    Mutlib AE; Diamond S; Shockcor J; Way R; Nemeth G; Gan L; Christ DD
    Xenobiotica; 2000 Nov; 30(11):1091-110. PubMed ID: 11197070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig.
    Barrett JS; Yu J; Kapil R; Padovani P; Brown F; Ebling WF; Corjay MH; Reilly TM; Bozarth JM; Mousa SA; Pieniaszek HJ
    Biopharm Drug Dispos; 1999 Sep; 20(6):309-18. PubMed ID: 10701702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
    Akkerhuis KM; van Den Brand MJ; van Der Zwaan C; Peels HO; Suryapranata H; van Der Wieken LR; Stibbe J; Hoffmann J; Baardman T; Deckers JW; Simoons ML
    Heart; 2001 Apr; 85(4):444-50. PubMed ID: 11250974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
    Refino CJ; Modi NB; Bullens S; Pater C; Lipari MT; Robarge K; Blackburn B; Beresini M; Weller T; Steiner B; Bunting S
    Thromb Haemost; 1998 Jan; 79(1):169-76. PubMed ID: 9459344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
    Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.
    Modi NB; Novotny W; Reimann JD; Cannon CP; Braunwauld E
    J Clin Pharmacol; 1999 Jul; 39(7):675-84. PubMed ID: 10392322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
    Pieniaszek HJ; Davidson AF; Walton HL; Pinto DJ; Olson RE; Reilly TM; Barrett YC
    J Pharm Biomed Anal; 2003 Jan; 30(5):1441-9. PubMed ID: 12467915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.